Bristol Myers Squibb has entered into a strategic collaboration with Microsoft to integrate advanced imaging technology and AI-driven analytics into oncology diagnostics. Microsoft’s imaging platforms, currently utilized by approximately 80% of U.S. hospitals, will be paired with Bristol Myers Squibb’s drug delivery and tumor biology expertise to develop an AI-enabled workflow aimed at earlier detection of lung cancer. The pilot phase will involve data from over 10,000 patient scans across five major cancer centers, with the goal of reducing time to diagnosis by 30% and improving tumor staging accuracy by 25%. If successful, the program could expand to breast and colorectal cancer indications within 18 months.

In December, Bristol Myers Squibb committed up to $850 million in a multi-year collaboration with Janux Therapeutics to co-develop next-generation T cell receptor agonists targeting solid tumors. The upfront payment of $50 million and an equity investment positions Bristol Myers Squibb to leverage Janux’s TRACTr platform, which has demonstrated in preclinical studies a two-fold increase in tumor infiltration compared to current bispecific antibody approaches. Early-stage trials are scheduled to begin in Q2 of this year, with the first clinical data readout expected in late 2025. This deal potentially opens up a multi-billion dollar market segment beyond the company’s existing hematology franchise.

Bristol Myers Squibb’s heart failure therapy, Camzyos, delivered 89% year-over-year revenue growth in 2025, reaching $380 million in annual sales. The company recently announced positive Phase 3 SCOUT-HCM results, demonstrating a 35% reduction in symptomatic obstruction events among obstructive hypertrophic cardiomyopathy patients. Based on these outcomes, Bristol Myers Squibb plans to file for a label extension in adolescent populations by mid-2026, potentially adding an addressable market of 15,000 patients in North America and Europe. The company also forecasts a 20% compound annual growth rate for Camzyos through 2028.

Bristol Myers Squibb’s late-stage pipeline includes six registrational trials with potential peak annual sales exceeding $1 billion each, spanning indications in multiple myeloma, metastatic colorectal cancer and neuropsychiatric disorders. Key readouts are anticipated in the next 12 months: a Phase 3 study of a novel BCL-2 inhibitor in relapsed lymphoma (data expected Q3) and a pivotal trial of a CNS-penetrant kinase inhibitor in treatment-resistant schizophrenia (data expected Q4). Management projects that successful launches from these programs could add $4 billion in incremental revenue by 2030, reinforcing the company’s long-term growth trajectory.